Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

James Flynn Reports a 4% Position in Cancer Genetics

A new filing with the Securities and Exchange Commission has revealed that James E. Flynn, and his hedge fund Deerfield Management now hold a 4.01% stake in Cancer Genetics Inc (NASDAQ:CGIX). The new position in the equity portfolio of Deerfield contains 354,180 shares.

Cancer Genetics

Disclosure: none

Recommended Reading:

Phil Frohlich & Prescott Continue to Buy China Marine Food Group

Hedge Fund Guru Donald Smith Increases Position in Alliance One to 10.26%

This Under-The-Radar Stock Could Save A Buffett Favorite Millions